Abstract:There is still an unmet need for patients with extensive small cell lung cancer (SCLC) who failed from the previous treatment even though topotecan was approved by Food and Drug Administration as second line setting in this population. Nab-paclitaxel (nab-P) has showed promising efficacy in pancreas cancer, breast cancer and nonsmall cell lung cancer, this phase II trial try to evaluate the safety and efficacy of nab-paclitaxel (nab-P) monotherapy as the secondary or later line therapy in patients with extensive SCLC. Main included criteria were performance status 0-2, extensive disease, failed or insensitive relapse from the previous treatment, sufficient myeloid function. Sensitive relapsed from the last line chemotherapy was excluded. Patients who met these criteria received weekly nab-paclitaxel 130mg/m2, d1,8,15, every 4 week or nab-paclitaxel of 230 mg/m2, d1 every 3 weeks. The Primary end point is objective response rate. The secondary end point included progression free survival (PFS), overall survival, and side effects. From Sep, 2014 to Mar, 2017, 40 patients were included into this study, included 39 males, 6 never smokers, PS 1/2:27/13 with a median age of 66 years. The median line of nab-P monotherapy is 3(2-5). Among them, 30 patients received weekly nab-P and 10 received nab-P every 3 weeks. 9, 27, 4 patients were resistant, refractory and sensitive relapse to first line chemotherapy respectively. 7 patients got partial response, 17 stable diseases and 16 progression disease. The objective response rate was 17.5% and disease control rate (DCR) was 60%. The median PFS was 3 months and during of response was 5.8 months. Subgroup analysis showed that patients who were refractory or sensitive relapse to first line chemotherapy had a significant higher DCR (67.8% vs 28.5%, p=0.042) and longer PFS (3.3 vs 1.4 months, p=0.04), while similar results were found in different PS, smoking status and lines of therapy. Toxicity was mild and manageable including alopecia, neuritis, neutropenia and anemia, no grade 3/4 adverse event observed. Nab-P showed promising efficacy together with acceptable toxicity in patients with extensive SCLC who failed or insensitive relapse from the previous treatment, especially in the subgroup of refractory or sensitive relapse to first line chemotherapy, large cohort study is needed to validate these findings.

Safety Analysis of Weekly Paclitaxel Plus S-1 Versus Paclitaxel Plus 5-Fluorouracil/calcium Folinate As First-Line Therapy in Advanced Gastric Cancer: a Multicenter Open Random Phase II Trial

[A Phase II Prospective Randomized Controlled Trial of Weekly Paclitaxel Combined with S-1 or Fluorouracil for Advanced Gastric Carcinoma].

A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.

A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

144O Comparison of Efficacy and Safety of Paclitaxel and Capecitabine Followed by Capecitabine As Maintenance Therapy Versus Cisplatin and Capecitabine Therapy for Advanced Gastric Cancer: a Multicentre, Randomised, Active-Controlled Phase III Study

Weekly Albumin-Bound Paclitaxel/cisplatin Versus Gemcitabine/cisplatin As First-Line Therapy for Patients with Advanced Non-Small-cell Lung Cancer: A Phase II Open-Label Clinical Study

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

Outcome of Advanced Nonsmall Cell Lung Cancer Patients Receiving Gemcitabine and Weekly Paclitaxel As First-Line Treatment

Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.

Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study.

[A Multicenter Randomized Clinical Trial of Weekly Paclitaxel and Carboplatin Vs Three Weeks Paclitaxel and Carboplatin As First Line Chemotherapy in Epithelial Ovarian Cancer].

A Phase II Trial of Weekly Paclitaxel and High-Dose 5-Fluorouracil Plus Leucovorin in Patients with Chemotherapy-Pretreated Metastatic Breast Cancer.

Randomized controlled trial of S-1 and paclitaxel in the treatment of metastatic gastric cancer

A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer

Biweekly S-1 Plus Paclitaxel (SPA) As Second-Line Chemotherapy after Failure from Fluoropyrimidine and Platinum in Advanced Gastric Cancer: a Phase II Study.

Comparison Of Efficacy And Safety Of Second-Line Palliative Chemotherapy With Paclitaxel Plus Raltitrexed And Paclitaxel Alone In Patients With Metastatic Gastric Adenocarcinoma: A Randomized Phase Ii Trial.

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy As 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

A Multicenter, Randomized Trial Comparing Efficacy and Safety of Paclitaxel/capecitabine and Cisplatin/capecitabine in Advanced Gastric Cancer

Efficiency and Toxicity of Biweekly Paclitaxel Combined with 5-Fu/leucovorin As Second-line Chemotherapy for Advanced or Recurrent Gastric Cancer